Fig. 1

Flow diagram demonstrating methods for identification of studies to assess the efficacy of denosumab or zoledronic acid (ZA) using symptomatic skeletal events(SSEs) as the primary end point in postmenopausal women with oestrogen-receptor-positive advanced breast cancer